{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:30:32Z","timestamp":1787135432905,"version":"build-2736575974"},"reference-count":18,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Extend Phase 2A study to evaluate additional concentrations of H-1337 and dosing frequencies, and to compare them with a positive control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Phase 2B, randomized, double-masked, active-controlled, dose\u2013response study of 28 days of four treatments: H-1337 0.6% b.i.d., 1.0% b.i.d., or 1.0% q.d. (1.0% in the morning with H-1337 vehicle in the evening), and timolol maleate 0.5% b.i.d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants:<\/jats:title>\n                    <jats:p>Two hundred one subjects with open-angle glaucoma or ocular hypertension at eight private practice sites in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Diurnal intraocular pressure (IOP) over 28 days of dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures:<\/jats:title>\n                    <jats:p>Non-inferiority to timolol in change from baseline in IOP at Day 1 and Day 28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Mean reduction in IOP was 4\u20137 mmHg for the H-1337 groups and 5\u20138 mmHg for the timolol group. Non-inferiority to timolol for H-1337 1.0% b.i.d. [upper limit of 95% confidence interval (CI) strictly lower than 1.5 mmHg] was met at 6\/9 time points (Day 1: h 8 and 12; Day 28: h 2, 4, 8, and 12). Similar comparative efficacy was seen for the other H-1337 treatment groups. The most common adverse event observed was hyperemia, reported in 54.0% (27\/50) for H-1337 1.0% q.d., 33.3% (17\/51) for H-1337 0.6% b.i.d., 41.2% (21\/51) for H-1337 1.0% b.i.d., and 8.2% (4\/49) for timolol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>H-1337 in doses of 0.6% b.i.d., 1.0% q.d., and 1.0% b.i.d. had ocular hypotensive efficacy in the range of timolol, although not within the strict Phase 3 non-inferiority margins, which would have required a larger sample size.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683251393984","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:53:42Z","timestamp":1762304022000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Double-Masked Controlled Trial of H-1337 as a Treatment for Glaucoma and Ocular Hypertension"],"prefix":"10.1177","volume":"42","author":[{"given":"Lee","family":"Shettle","sequence":"first","affiliation":[{"name":"Shettle Eye Research, Largo, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Mulaney","sequence":"additional","affiliation":[{"name":"Central Florida Eye Associates, Lakeland, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Williams","sequence":"additional","affiliation":[{"name":"PRN Pharmaceutical Research Network, Cheyenne, Wyoming, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beck","sequence":"additional","affiliation":[{"name":"PRN Pharmaceutical Research Network, Cheyenne, Wyoming, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette A.","family":"Stewart","sequence":"additional","affiliation":[{"name":"PRN Pharmaceutical Research Network, Cheyenne, Wyoming, USA."},{"name":"PharmaLogic Development, Inc., San Rafael, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Novack","sequence":"additional","affiliation":[{"name":"PharmaLogic Development, Inc., San Rafael, California, USA."},{"name":"Department of Ophthalmology &amp; Vision Science, University of California School of Medicine, Davis, San Rafael, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"Preferred Practice Pattern: Primary Open-Angle Glaucoma","author":"Ameican Academy of Ophthalmology","year":"2015","unstructured":"Ameican Academy of Ophthalmology. Preferred Practice Pattern: Primary Open-Angle Glaucoma. Ameican Academy of Ophthalmology; 2015."},{"key":"e_1_3_3_3_2","volume-title":"Terminology and Guidelines for Glaucoma","author":"Society EG","year":"2014","unstructured":"Society EG. Terminology and Guidelines for Glaucoma, 4th ed. PubliComm: Savona, Italy; 2014.","edition":"4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13989"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2024.2311669"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.01.003"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.11.019"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.0525"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.11.017"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06192-0"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01277-2"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2019.03.007"},{"issue":"7","key":"e_1_3_3_13_2","first-page":"5712","article-title":"A novel isoquinoline sulfonamide protein kinase inhibitor (H-1337) produces long-lasting reduction of IOP","volume":"56","author":"Hidaka H","year":"2015","unstructured":"Hidaka H, , Sumi K, , Izuhara T, et al. A novel isoquinoline sulfonamide protein kinase inhibitor (H-1337) produces long-lasting reduction of IOP. Invest Ophthal Vis Sci, 2015; 56(7):5712.","journal-title":"Invest Ophthal Vis Sci"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2022.08.015"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2025.02.004"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.12.026"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.96"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00760-6"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.9.1230"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683251393984","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251393984","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251393984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:14:54Z","timestamp":1787134494000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683251393984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1177\/10807683251393984"],"URL":"https:\/\/doi.org\/10.1177\/10807683251393984","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}